Literature DB >> 25749828

Regulatory T cells and progenitor B cells are independent prognostic predictors in lower risk myelodysplastic syndromes.

Josephine D Kahn1, Martine E D Chamuleau1, Theresa M Westers1, Peter M Van de Ven1, Linda van Dreunen1, Margot van Spronsen1, Gert J Ossenkoppele1, Arjan A van de Loosdrecht2.   

Abstract

Entities:  

Keywords:  myelodysplastic syndrome; progenitor B cells; prognosis; regulatory T cells

Mesh：

Year:  2015        PMID： 25749828      PMCID： PMC4450633          DOI： 10.3324/haematol.2014.116657

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  11 in total

1.  Multicenter validation of a reproducible flow cytometric score for the diagnosis of low-grade myelodysplastic syndromes: results of a European LeukemiaNET study.

Authors:  Matteo G Della Porta; Cristina Picone; Cristiana Pascutto; Luca Malcovati; Hideto Tamura; Hiroshi Handa; Magdalena Czader; Sylvie Freeman; Paresh Vyas; Anna Porwit; Leonie Saft; Theresia M Westers; Canan Alhan; Claudia Cali; Arjan A van de Loosdrecht; Kiyoyuki Ogata
Journal:  Haematologica       Date:  2012-02-07       Impact factor: 9.941

2.  Immune mediated autologous cytotoxicity against hematopoietic precursor cells in patients with myelodysplastic syndrome.

Authors:  Martine E D Chamuleau; Theresia M Westers; Linda van Dreunen; Judith Groenland; Adri Zevenbergen; Corien M Eeltink; Gert J Ossenkoppele; Arjan A van de Loosdrecht
Journal:  Haematologica       Date:  2009-02-19       Impact factor: 9.941

3.  Revised international prognostic scoring system for myelodysplastic syndromes.

Authors:  Peter L Greenberg; Heinz Tuechler; Julie Schanz; Guillermo Sanz; Guillermo Garcia-Manero; Francesc Solé; John M Bennett; David Bowen; Pierre Fenaux; Francois Dreyfus; Hagop Kantarjian; Andrea Kuendgen; Alessandro Levis; Luca Malcovati; Mario Cazzola; Jaroslav Cermak; Christa Fonatsch; Michelle M Le Beau; Marilyn L Slovak; Otto Krieger; Michael Luebbert; Jaroslaw Maciejewski; Silvia M M Magalhaes; Yasushi Miyazaki; Michael Pfeilstöcker; Mikkael Sekeres; Wolfgang R Sperr; Reinhard Stauder; Sudhir Tauro; Peter Valent; Teresa Vallespi; Arjan A van de Loosdrecht; Ulrich Germing; Detlef Haase
Journal:  Blood       Date:  2012-06-27       Impact factor: 22.113

4.  Expansion of effector memory regulatory T cells represents a novel prognostic factor in lower risk myelodysplastic syndrome.

Authors:  Adam W Mailloux; Chiharu Sugimori; Rami S Komrokji; Lili Yang; Jaroslaw P Maciejewski; Mikkael A Sekeres; Ronald Paquette; Thomas P Loughran; Alan F List; Pearlie K Epling-Burnette
Journal:  J Immunol       Date:  2012-08-08       Impact factor: 5.422

5.  Evidence for reduced B-cell progenitors in early (low-risk) myelodysplastic syndrome.

Authors:  Alexander Sternberg; Sally Killick; Tim Littlewood; Chris Hatton; Andy Peniket; Thomas Seidl; Shamit Soneji; Joanne Leach; David Bowen; Claire Chapman; Graham Standen; Edwin Massey; Lisa Robinson; Bipin Vadher; Richard Kaczmarski; Riaz Janmohammed; Kim Clipsham; Andrew Carr; Paresh Vyas
Journal:  Blood       Date:  2005-08-02       Impact factor: 22.113

6.  The effects of 5-azacytidine on the function and number of regulatory T cells and T-effectors in myelodysplastic syndrome.

Authors:  Benedetta Costantini; Shahram Y Kordasti; Austin G Kulasekararaj; Jie Jiang; Thomas Seidl; Pilar Perez Abellan; Azim Mohamedali; Nicolas Shaun B Thomas; Farzin Farzaneh; Ghulam J Mufti
Journal:  Haematologica       Date:  2012-12-14       Impact factor: 9.941

7.  IL-17-producing CD4(+) T cells, pro-inflammatory cytokines and apoptosis are increased in low risk myelodysplastic syndrome.

Authors:  Shahram Y Kordasti; Behdad Afzali; Ziyi Lim; Wendy Ingram; Janet Hayden; Linda Barber; Katie Matthews; Rajani Chelliah; Barbara Guinn; Giovanna Lombardi; Farzin Farzaneh; Ghulam J Mufti
Journal:  Br J Haematol       Date:  2009-02-03       Impact factor: 6.998

8.  Clinical significance of regulatory T cells in patients with myelodysplastic syndrome.

Authors:  Wedad Hamdi; Hatsue Ogawara; Hiroshi Handa; Norifumi Tsukamoto; Yoshihisa Nojima; Hirokazu Murakami
Journal:  Eur J Haematol       Date:  2008-11-10       Impact factor: 2.997

Review 9.  Dendritic cells in myelodysplastic syndromes: from pathogenesis to immunotherapy.

Authors:  Nathalie Kerkhoff; Hetty J Bontkes; Theresia M Westers; Tanja D de Gruijl; Shahram Kordasti; Arjan A van de Loosdrecht
Journal:  Immunotherapy       Date:  2013-06       Impact factor: 4.196

10.  CD4+CD25high Foxp3+ regulatory T cells in myelodysplastic syndrome (MDS).

Authors:  Shahram Y Kordasti; Wendy Ingram; Janet Hayden; David Darling; Linda Barber; Behdad Afzali; Giovanna Lombardi; Marcin W Wlodarski; Jaroslaw P Maciejewski; Farzin Farzaneh; Ghulam J Mufti
Journal:  Blood       Date:  2007-04-05       Impact factor: 22.113
View more
  5 in total

Review 1.  Is There a Role for Flow Cytometry in the Evaluation of Patients With Myelodysplastic Syndromes?

Authors:  Anna Porwit
Journal:  Curr Hematol Malig Rep       Date:  2015-09       Impact factor: 3.952

2.  Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions.

Authors:  Peter Valent; Attilio Orazi; David P Steensma; Benjamin L Ebert; Detlef Haase; Luca Malcovati; Arjan A van de Loosdrecht; Torsten Haferlach; Theresia M Westers; Denise A Wells; Aristoteles Giagounidis; Michael Loken; Alberto Orfao; Michael Lübbert; Arnold Ganser; Wolf-Karsten Hofmann; Kiyoyuki Ogata; Julie Schanz; Marie C Béné; Gregor Hoermann; Wolfgang R Sperr; Karl Sotlar; Peter Bettelheim; Reinhard Stauder; Michael Pfeilstöcker; Hans-Peter Horny; Ulrich Germing; Peter Greenberg; John M Bennett
Journal:  Oncotarget       Date:  2017-07-05

3.  Regulatory T Cells and Profile of FOXP3 Isoforms Expression in Peripheral Blood of Patients with Myelodysplastic Syndromes.

Authors:  Galina A Dudina; Almira D Donetskova; Marina M Litvina; Alexander N Mitin; Tatiana A Mitina; Sergey A Polyakov
Journal:  Adv Hematol       Date:  2018-10-10

4.  Thrombomodulin-expressing monocytes are associated with low-risk features in myelodysplastic syndromes and dampen excessive immune activation.

Authors:  Nathalie van Leeuwen-Kerkhoff; Theresia M Westers; Pino J Poddighe; Tanja D de Gruijl; Shahram Kordasti; Arjan A van de Loosdrecht
Journal:  Haematologica       Date:  2019-07-04       Impact factor: 9.941

Review 5.  Diagnosis of Myelodysplastic Syndromes: From Immunological Observations to Clinical Applications.

Authors:  Yannick Simoni; Nicolas Chapuis
Journal:  Diagnostics (Basel)       Date:  2022-07-07
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.